CATHETER PRECISION INC (VTAK) Fundamental Analysis & Valuation

NYSEARCA:VTAK • US74933X7084

Current stock price

1.21 USD
+0.35 (+40.37%)
At close:
1.18 USD
-0.03 (-2.48%)
After Hours:

This VTAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. VTAK Profitability Analysis

1.1 Basic Checks

  • In the past year VTAK has reported negative net income.
  • In the past year VTAK has reported a negative cash flow from operations.
  • VTAK had negative earnings in each of the past 5 years.
  • In the past 5 years VTAK always reported negative operating cash flow.
VTAK Yearly Net Income VS EBIT VS OCF VS FCFVTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -87.12%, VTAK is not doing good in the industry: 79.79% of the companies in the same industry are doing better.
  • With a Return On Equity value of -327.20%, VTAK is not doing good in the industry: 80.85% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -87.12%
ROE -327.2%
ROIC N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
VTAK Yearly ROA, ROE, ROICVTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • Looking at the Gross Margin, with a value of 92.60%, VTAK belongs to the top of the industry, outperforming 97.87% of the companies in the same industry.
  • VTAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTAK Yearly Profit, Operating, Gross MarginsVTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. VTAK Health Analysis

2.1 Basic Checks

  • VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • VTAK has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, VTAK has a worse debt to assets ratio.
VTAK Yearly Shares OutstandingVTAK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K
VTAK Yearly Total Debt VS Total AssetsVTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -18.34, we must say that VTAK is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -18.34, VTAK is doing worse than 88.83% of the companies in the same industry.
  • VTAK has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.04, VTAK is in the better half of the industry, outperforming 69.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -18.34
ROIC/WACCN/A
WACC7.38%
VTAK Yearly LT Debt VS Equity VS FCFVTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • VTAK has a Current Ratio of 0.46. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.46, VTAK is not doing good in the industry: 92.55% of the companies in the same industry are doing better.
  • VTAK has a Quick Ratio of 0.46. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.46, VTAK is not doing good in the industry: 91.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.46
Quick Ratio 0.46
VTAK Yearly Current Assets VS Current LiabilitesVTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. VTAK Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 83.78% over the past year.
  • The Revenue has grown by 82.96% in the past year. This is a very strong growth!
  • The Revenue has been growing by 167.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)83.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.53%
Revenue 1Y (TTM)82.96%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%135.42%

3.2 Future

  • The Earnings Per Share is expected to grow by 40.75% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, VTAK will show a very strong growth in Revenue. The Revenue will grow by 312.31% on average per year.
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VTAK Yearly Revenue VS EstimatesVTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
VTAK Yearly EPS VS EstimatesVTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2023 2024 2025 2026 -200K -400K -600K -800K -1M

More info and screens

Find the best growth stocksShow best growing peers

1

4. VTAK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VTAK. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTAK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTAK Price Earnings VS Forward Price EarningsVTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTAK Per share dataVTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • VTAK's earnings are expected to grow with 40.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.75%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VTAK Dividend Analysis

5.1 Amount

  • No dividends for VTAK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VTAK Fundamentals: All Metrics, Ratios and Statistics

CATHETER PRECISION INC

NYSEARCA:VTAK (4/9/2026, 7:24:31 PM)

After market: 1.18 -0.03 (-2.48%)

1.21

+0.35 (+40.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-19
Earnings (Next)05-12
Inst Owners16.42%
Inst Owner Change0%
Ins Owners22.63%
Ins Owner Change4.3%
Market Cap2.86M
Revenue(TTM)730.00K
Net Income(TTM)-22.19M
Analysts85.71
Price Target38.76 (3103.31%)
Short Float %10.83%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-73.3%
Min Revenue beat(2)-81.54%
Max Revenue beat(2)-65.07%
Revenue beat(4)0
Avg Revenue beat(4)-62.79%
Min Revenue beat(4)-81.54%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-69.05%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.91
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-37.38
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4.09
OCFYN/A
SpS0.31
BVpS2.87
TBVpS-6.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.12%
ROE -327.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.6%
FCFM N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.41%
Cap/Sales 6.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.46
Quick Ratio 0.46
Altman-Z -18.34
F-Score4
WACC7.38%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.53%
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)82.96%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%135.42%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.66%
OCF growth 3YN/A
OCF growth 5YN/A

CATHETER PRECISION INC / VTAK Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CATHETER PRECISION INC (VTAK) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VTAK.


What is the valuation status for VTAK stock?

ChartMill assigns a valuation rating of 1 / 10 to CATHETER PRECISION INC (VTAK). This can be considered as Overvalued.


What is the profitability of VTAK stock?

CATHETER PRECISION INC (VTAK) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CATHETER PRECISION INC?

The Earnings per Share (EPS) of CATHETER PRECISION INC (VTAK) is expected to grow by 96.27% in the next year.